The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
Blood Markers of Early Pancreas Cancer

Blood Markers of Early Pancreas Cancer

Clinicaltrials.gov identifier:
NCT03568630

Prevention:
Pancreatic

Study Contact Information:

For additional information, please contact: Christina L Hoy, DNP by phone: 402-559-1577 or by email, or
Kelsey A Klute, MD by phone: 402-559-8500 or by email


Blood Markers of Early Pancreas Cancer

About the Study

The purpose of this study is to try to find markers of early pancreatic cancer for screening for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.

What the Study Entails

Each study participant will undergo blood tests that measure a blood sugar marker called Hemoglobin A1c as well as other markers.

Participants may include people at high risk for pancreatic cancer due to the following: 

  • people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk
  • people with cystic pancreas lesions or chronic pancreatitis
  • people with new-onset diabetes.   

Study participants will be followed for five years.

Study Site

  • Omaha, Nebraska
    Nebraska Medical Center
    Contact: Christina Hoy, DNP by phone: 402-559-1577 or by email            
This Study is Open To:

Men and women age 19 years or older can be considered for enrollment in this study if they meet one of the following criteria:

  • Have new onset type 2 diabetes, or are considered high-risk pre-diabetes
  • Have pancreatic neoplasms (abnormal growths) or pancreatitis
  • Have family history of pancreatic cancer or have an increased risk due to an inherited mutation in any one of the following genes: BRCA1, BRCA2, PALB2, MLH1, MSH2, MSH6, PMS2, APC, CKDN2a, p16, STK11, ATM, SMAD4, BMPR1A, TP53, CFTR
This Study is Not Open To:
  • Patients with a personal history of pancreatic cancer
  • Patients who are currently receiving treatment for a cancer diagnosis (excluding long-term hormonal therapy)
  • Patients who are pre-diabetic and taking metformin for 3 or more years